Bryan, Garnier & Co acts as joint bookrunner for a €45 million private placement for Ablynx

Paris, March 6th, 2013 – Bryan, Garnier & Co, the independent pan-European Investment bank focusing on growth companies, acts as joint bookrunner for a €45 million private placement for Ablynx, including €31.5 million of new shares.

This new placement will allow Ablynx to:

• Maintain the momentum of ALX-0061 and review paths which could allow the value of this asset to be maximized

• Flexibly manage the structure of timing of potential deals

• Initiate, advance and/or accelerate the pre-clinical development for various programs

Ablynx is a biopharmaceutical company headquartered in Ghent, Belgium. With its proprietary technology platform, Nanobody, a novel class of therapeutic proteins based on single-domain antibody fragments, Ablynx has built multiple programs targeting various diseases, including inflammation, oncology, and Alzheimer’s disease, and also collaborated with leading pharmaceutical companies in the industry.

In spite of challenging equity markets, the success of this placement indicates strong investor appetite for promising European healthcare mid-cap companies investing in future developments. Furthermore, the market remains an efficient purveyor of liquidity for the historical shareholders of mid-cap companies such as venture capital and private equity funds.

Bryan, Garnier & Co acted as Joint Bookrunner for the placement.

For more information please contact Anna Emelianenko /+33 (0) 1 56 68 75 67 / aemelianenko@bryangarnier.com

About Ablynx

Headquartered in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases including inflammation, haematology, oncology and pulmonary disease. To date, Ablynx has generated Nanobodies against more than 235 different disease targets and has approximately 25 programs in the pipeline and 5 nanobodies at the clinical development stage. Due to its proprietary technology platform, Nanobody, and its experienced management team, Ablynx has already successfully built collaborations with many leading pharmaceutical companies including Boehringer Ingelheim, Merck Serono, Novartis and Merck & Co. The successful Phase II results of Ablynx’s flagship product, ALX-0061, which targets at the treatment of rheumatoid arthritis have been published in Feb 2013.

www.ablynx.com